Table 1.

Primary antibodies used in this study.

Antibody	Immunogen	Source	Working Dilution	RRID
CB	Recombinant protein specific to amino terminus of human CB	Cell Signaling Technology, Danvers, MA, USA	DAB 1:500, IF 1:200	AB_2687400
CB1R	Fusion protein containing aa 1–77 of rat CB1R	Calbiochem, Gibbstown, NJ, USA	DAB 1:300, IF 1:200, WB 1:1,000	AB_211563
CTIP2	Synthetic peptide corresponding to aa 1–150 of human Ctip2	Abcam plc., Cambridge, UK	IF 1:200	AB_2064130
FAAH	Synthetic peptide corresponding to aa 561–579 of rat FAAH	Cayman Chemical, Ann Arbor, MI, USA	DAB 1:200, IF 1:200, WB 1:1,000	AB_10078701
GFAP	GFAP purified from pig spinal cord	Cell Signaling Technology, Danvers, MA, USA	IF 1:200	AB_561049
NAPE-PLD	Synthetic peptide from human NAPE-PLD aa 159–172	Cayman Chemical, Ann Arbor, MI, USA	DAB 1:200, IF 1:200, WB 1:1,000	AB_10507996
PV	Parvalbumin purified from carp muscle	Swant, Marly, Fribourg, Switzerland	IF 1:200	AB_10000343
TH	TH purified from PC12 cells derived from rat pheochromocytoma; recognizes an epitope on the outside of the regulatory N-terminus of TH	EMD Millipore, Chemicon, Temecula, CA, USA	IF 1:200	AB_2201528

CB: Calbindin-d28k; CB1R: cannabinoid receptor type 1; CTIP2: CTIP2 transcription factor; DAB: 3,3′-diaminobenzidine immunostaining; FAAH: fatty acid amide hydrolase; GFAP: glial fibrillary acidic protein; IF: immunofluorescence; NAPE-PLD: N-acyl phosphatidylethanolamine-specific phospholipase D; PV: parvalbumin; TH: tyrosine hydroxylase; WB: Western blot.